BioLineRx Ltd (BLRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.49 (-1.70%), Market cap $0.01B, 52-week low–high $2.18 ~ $5.93.
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered
Financial statements, price targets, institutional (13F) holdings and related news for BioLineRx Ltd are updated in real time on BlackAll Trade.
BioLineRx Ltd trades at $2.49 (-1.70%). Real-time quotes and charts are available on BlackAll Trade.
BioLineRx Ltd has a market cap of about $0.01B.
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damag